Betty Mays
Family · Mooresville, NCNPI 1881913382
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 848 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $4,199 and has fallen 56.0% since, to $1,849 in 2025. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 848 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$825
- Neurelis, Inc.$795
- Novartis$760
- Lundbeck LLC$614
- Eisai Inc.$587
- plus $10K from 54 others
What the payments were for
- Food & beverage$14,93199%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$125
How this compares
$15,042 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 45 | $67,048 |
| AptiomEslicarbazepine Acetate | 32 | $55,219 |
| NucyntaTapentadol Hcl | 51 | $54,097 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 272 | $52,309 |
| FycompaPerampanel | 40 | $48,957 |
| Nurtec OdtRimegepant Sulfate | 26 | $43,980 |
| Levorphanol Tartrate | 15 | $42,997 |
| Xtampza ErOxycodone Myristate | 38 | $22,253 |
| BelbucaBuprenorphine Hcl | 30 | $18,199 |
| MovantikNaloxegol Oxalate | 40 | $18,105 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 533 | $16,449 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $15,311 |
| Buprenorphine | 62 | $14,321 |
| SymproicNaldemedine Tosylate | 25 | $11,315 |
| ZtlidoLidocaine | 22 | $10,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca | $500 | $94,550119 claims |
| UCB, Inc.Briviact | $543 | $67,04845 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $361 | $55,21932 claims |
| Eisai Inc.Fycompa | $587 | $48,95740 claims |
| PfizerNurtec Odt, Dilantin | $543 | $46,92844 claims |
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $175 | $42,99715 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $173 | $10,82922 claims |
| AbbVieLinzess | $1,407 | $8,08415 claims |
| Upsher-smith Laboratories LLCTopiramate | $238 | $34028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Mooresville
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.